XNK Therapeutics: Our goal is to help cancer patients live longer
XNK Therapeutics pioneers autologous natural killer (NK) cell therapies, aiming to extend the lives of cancer patients. With a Phase II clinical trial in progress for multiple myeloma treatment, the company's presence in Flemingsberg signifies a hub of innovation and collaboration, propelling them towards unprecedented advancements in cancer care.
What is your business concept? What problem are you out to solve?
“Our goal is to help cancer patients live longer. XNK Therapeutics was founded in 2012 and is one of the pioneers in cell therapy and we focus on cancer treatment by developing new cell-based treatments with autologous natural killer (NK) cells.”
“We have an innovative and world-leading platform technology that gives us a prominent position in autologous NK cell therapies,” says Johan Liwing, CEO of XNK Therapeutics.
Where are you now?
“We have established a leading position in the field of autologous NK cell therapies. This summer, the first patient was recruited for an investigator-initiated Phase II clinical trial in which our leading drug candidate is combined with Sanofi’s anti-CD38 antibody Sarclisa (Isatuximab), to treat multiple myeloma, a serious cancer. The study is being carried out at Karolinska University Hospital in Flemingsberg with Hareth Nahi at the helm as the main examiner, through our close collaboration with Karolinska Institutet, and Vecura, which contributes infrastructure for clinical regenerative medicine.”
“During the past year, we have grown from a company of two to 19 people. Today we have a very good management team including, among others, Michael Uhlin as Chief Scientific Officer and Johan Aschan as Chief Medical Officer. We are well placed to further accelerate our development with the goal of maintaining a world-leading position.”
What are your plans for the future?
“Our current focus is primarily on bringing our drug candidate for the treatment of multiple myeloma to the market. Then we want to broaden our platform to include more cancers.”
“We recently started the construction of a new GMP facility with an associated research laboratory of 350 square meters for our NK cell therapy. The new facility is being built at Novum in Flemingsberg and, once the facility is completed in 2022, it will give us complete control over the entire development chain.”
Why are you in Flemingsberg?
“Flemingsberg is the place in the world you want to be if you work with NK cells. There is a strong research facility here with a world-leading research group and proximity to a clinic that really knows NK cells.”
“Up to now our production has been at Vecura in Flemingsberg, which is one of the country’s leading production units for advanced therapy drugs and cells for transplantation. When we move to our own, new facility, we will be able to further increase our research and development capacity. In short, there is everything we need in Flemingsberg – there is nowhere like it elsewhere in the world.”
CONTACT
Hälsovägen 7, Novum
141 57 Huddinge
SVERIGE
E-post: info@xnktherapeutics.com
Hitchhiker’s Guide to Startup Success: Mastering the Art of the Perfect Pitch
Earlier this fall, we launched the first event in our seminar series, Hitchhiker’s Guide to Startup Success, which we are organizing together with Miltenyi Biotec. The inaugural session featured an inspiring workshop led by pitch expert and coach Malcolm Larri. The event gathered innovators and entrepreneurs in the Life Sciences sector, with a particular focus on Advanced Therapy Medicinal Products (ATMP)—a rapidly growing field with tremendous potential to revolutionize healthcare.
Key2Compliance Becomes a Trusted Partner in Strategic Collaboration to Advance ATMP and Life Science Development in Flemingsberg
Key2Compliance has become a Trusted Partner to Flemingsberg Science Foundation, a strategic collaboration aimed at promoting and strengthening the development of ATMP (Advanced Therapy Medicinal Products) and the Life Science sector in Flemingsberg.
AWA Becomes a Trusted Partner in Strategic Collaboration to Advance ATMP and Life Science Development in Flemingsberg
AWA has become a Trusted Partner to Flemingsberg Science Foundation, a strategic collaboration aimed at promoting and strengthening the development of ATMP (Advanced Therapy Medicinal Products) and the Life Science sector in Flemingsberg.
Flemingsberg’s Role in Advancing Life Science in Southern Stockholm
During Almedalen week this year, we had the opportunity to delve into Flemingsberg’s significance for southern Stockholm as a world-leading player in life science. The purpose of the roundtable discussion was to raise awareness about Flemingsberg’s development in life science and create a platform for the exchange of experiences. We shared valuable insights on how Flemingsberg can become one of Sweden’s most significant centers for education, research, and creativity.
